Retatrutide Price – GLP-3 R Research Peptide

Product Overview

When researchers search for retatrutide price, they are typically looking for a reliable, lab-tested triple agonist peptide for metabolic research. Retatrutide (often referred to as GLP-3 R) is an investigational once-weekly triple hormone receptor agonist that simultaneously activates glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors . This multi-target mechanism distinguishes it from dual agonists and single-pathway compounds.

Understanding retatrutide price begins with recognizing that this compound is supplied strictly for laboratory investigation of incretin signaling, metabolic regulation, and adipose tissue biology. Retatrutide has demonstrated superior metabolic effects in clinical trials, with phase 3 studies showing marked dose-dependent reductions in body weight .

Important Notice: Retatrutide is an investigational medicine that has not been approved by the FDA. It is only available to participants in clinical trials and cannot be legally purchased, prescribed, or compounded . The World Health Organization has issued global guidelines on GLP-1 medicines, though retatrutide specifically remains under investigation . Any listing claiming to represent a legitimate retatrutide price outside a clinical-trial setting should be treated with extreme caution. This product is supplied for research purposes only and is not intended for human consumption or clinical use.

Product Specifications

Mechanism of Action

Triple Receptor Agonism

Retatrutide is a single-molecule agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors . Unlike currently available therapies that primarily target one or two metabolic pathways, retatrutide’s triple mechanism is designed to enhance weight reduction while improving glucose regulation and broader cardiometabolic health.

The GIP and GLP-1 receptor components promote insulin secretion, delay gastric emptying, and modulate appetite through central nervous system effects. The addition of glucagon receptor agonism—the third pathway unique to retatrutide—is believed to boost caloric burn and promote fat cell breakdown. Research published in Biomolecules highlights retatrutide as a groundbreaking advancement in obesity and type 2 diabetes pharmacotherapy .

Multi-Omic Profiling Insights

Recent research has revealed that retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair mechanisms. A preclinical study published through the National Institutes of Health demonstrated that retatrutide inhibits the hexosamine biosynthetic pathway and YAP O-GlcNAcylation, leading to increased YAP degradation and decreased tumor size in obese triple-negative breast cancer models . These findings add context to ongoing discussions about retatrutide price and its perceived research value.

Research Applications

Metabolic and Glycemic Regulation Studies

Retatrutide has been extensively studied for its effects on glucose homeostasis. A phase 3 trial published in The Lancet evaluated the efficacy and safety of retatrutide in people with type 2 diabetes and inadequate glycaemic control . The TRANSCEND-T2D-1 trial represents one of the most rigorous investigations of the compound’s glycemic effects to date. Labs comparing retatrutide price against research value should note the depth of this clinical dataset.

Body Composition Research

Clinical studies have demonstrated substantial weight loss with retatrutide. Phase 3 trials have shown weight reductions exceeding 20% in adults with severe obesity and established cardiovascular disease. These effects are mediated through reduced appetite, slowed gastric emptying, and increased energy expenditure via glucagon receptor activation. The National Institutes of Health maintains a comprehensive database of retatrutide clinical research . Investigators evaluating retatrutide price for multi-arm studies should factor in batch consistency across large orders.

Cardiovascular and Metabolic Markers

Retatrutide has demonstrated meaningful improvements in cardiovascular risk factors including reductions in triglycerides, non-HDL cholesterol, systolic blood pressure, waist circumference, and high-sensitivity C-reactive protein. The European Association for the Study of Obesity has published new guidance positioning incretin mimetics as first-line pharmacologic treatments for obesity and its complications .

Adipose Tissue Biology Research

Multi-omic profiling studies have identified that retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair. Research published through PubMed has explored the triple-agonist revolution and the paradigm shift in multi-hormonal pharmacotherapy for obesity and cardiometabolic comorbidities .

Current Research Landscape

Retatrutide has completed multiple Phase 3 studies, with Eli Lilly reporting plans to submit a Biologics License Application to the FDA. A regulatory filing is not the same as an approval, and timelines can change. As of 2026, retatrutide remains an investigational drug and is not available to the public at any pharmacy . This is precisely why any advertised retatrutide price should be scrutinized carefully.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued warnings that retatrutide has not been authorised for medicinal use in the UK and cannot be legally supplied outside of ongoing clinical trials . The agency has conducted raids on illegal manufacturing facilities and seized thousands of doses of weight-loss medicines including retatrutide. The World Health Organization has published global guidelines on GLP-1 medicines for obesity . Researchers tracking retatrutide price trends should monitor these regulatory developments closely.

Quality and Purity

Each batch of Penguin Peptides Retatrutide (GLP-3 R) undergoes rigorous quality control:

• ≥98% purity verified by HPLC

• Correct molecular weight confirmed by mass spectrometry

• Third-party tested with Certificates of Analysis (COA) available

• Sterility and mycoplasma tested

Research-grade peptides differ significantly from FDA-approved pharmaceutical products. Retatrutide is investigational and has not been found safe and effective for any condition. When evaluating any retatrutide price, verifying COA documentation and purity specifications is the most important step in ensuring research validity.

Frequently Asked Questions

What is retatrutide (GLP-3 R)?

Retatrutide is an investigational triple hormone receptor agonist that simultaneously activates GIP, GLP-1, and glucagon receptors . It is sometimes called “GLP-3” because of its three receptor targets.

Is retatrutide FDA approved?

No. As of 2026, retatrutide is an investigational medication that has not been approved by the FDA . Eli Lilly has announced plans to submit a Biologics License Application.

Why is there no legitimate retatrutide price?

Retatrutide does not have a published U.S. list price because it remains investigational and is not FDA-approved. It is not commercially available through ordinary prescribing, telehealth, retail pharmacy, compounding pharmacy, or direct-to-consumer purchase . Any online retatrutide price listing should therefore be treated as unverified.

What research applications is retatrutide used for?

Retatrutide is studied in metabolic regulation, glycemic control, body composition research, adipose tissue biology, and cardiovascular risk factor analysis.

How should retatrutide be stored?

Store lyophilized powder at -20°C for long-term stability. Reconstituted material should be stored at 2–8°C and used promptly following standard laboratory protocols.

Is this product suitable for human use?

No. This product is supplied for research purposes only and is not intended for human consumption or clinical application.

Conclusion

Retatrutide (GLP-3 R) represents a valuable research tool for investigating triple hormone receptor agonism, metabolic regulation, and adipose tissue biology. With its unique GIP/GLP-1/glucagon mechanism, this peptide enables researchers to study multi-pathway incretin signaling in controlled laboratory settings.

For scientists searching for retatrutide price, it is essential to understand that legitimate retatrutide is not commercially available and any online offering should be treated with extreme caution . Another consideration when comparing retatrutide price across suppliers involves bulk quantities for multi-arm studies, which this product supports through consistent batch-to-batch performance. The World Health Organization has emphasized that GLP-1 medicines should be part of comprehensive care . This research-grade compound offers a reliable reference standard for laboratory investigation, with verified purity and comprehensive quality documentation.

Ready to Advance Your Research?

[Shop Retatrutide Now] – Order premium Retatrutide (GLP-3 R) for your laboratory today.

[Contact Our Research Team] – Reach out for COA requests or technical inquiries.